Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.

-Early separation from placebo observed in 100MTT, with improvements in ambulation evident as early as three months following initiation of BBP-418 treatment - Based on the positive interim analysis ...

The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. The Index seeks to track the performance of ...

(RTTNews) - BridgeBio Pharma Inc. (BBIO) said that it will no longer be pursuing development of BBP-631 for Congenital Adrenal Hyperplasia. The company is actively seeking partnership opportunities to ...

BBP-398 is a selective allosteric SHP2 inhibitor designed to inhibit mitogen-activated protein kinase (MAPK) pathway–driven tumors. We performed the first-in-human phase 1 trial described herein to ...

Barghest Building Performance (BBP) announced yesterday that it has received up to SGD45 million (US$32.8 million) investment from global investment firm KKR. BBP is a Singapore-based provider of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...